Participate in Research at CU Anschutz

This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase of the trial, where efficacy of pre-determined dose will be preliminarily assessed.

This study is designed to test the experimental combination of Losartan and Sunitinib in the hope of finding a drug combination that is safe and effective against osteosarcoma that has come back or not responded to standard therapy. There are two parts to this study. The first part is the dose-escalation phase. The main goal in this part of the study is to measure safety and side effects. Participants enrolled early will receive a lower dose of Losartan. Participants enrolled later will receive a higher dose of Losartan if lower doses appeared safe. The dose of Sunitinib may also be increased. The second part is called the dose-expansion phase. All participants will receive the same amount of Losartan and Sunitinib.